M. Melikoglu, I. Fresko, C. Mat, Y. Ozyazgan, F. Gogus, S. Yurdakul, V. Hamuryudan and H. Yazici, “Short-Term Trial of Etanercept in Behcet’s Disease: A Double Blind, Placebo Controlled Study,” The Journal of Rheumatology, Vol. 32, No. 1, 2005, pp. 98-105.

has been cited by the following article:

• TITLE: Efficacy of Infliximab Therapy for a Patient with Superficial Thrombophlebitis and Rheumatoid Arthritis

  AUTHORS: Masahiro Tada, Kazuyoshi Fukai, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Hiroaki Nakamura, Tatsuya Koike

  KEYWORDS: Infliximab, Superficial Thrombophlebitis, Treatment, Rheumatoid Arthritis, Tumor Necrosis Factor α

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.2 No.4, September 30, 2011

  ABSTRACT: Superficial thrombophlebitis is known as a frequent complication of Behçet’s disease. Infliximab may promote healing of superficial thrombophlebitis in patients with Behçet’s disease. However, thrombophlebitis as a complication of rheumatoid arthritis (RA) is rare and treatments have not been reported. We describe the case of a 47-year-old man with RA with complications of superficial thrombophlebitis who was treated using methotrexate and infliximab. Erythema nodosum and cord-like induration with pain in the extremities completely disappeared following a single infusion of infliximab and oral acetylsalicylic acid was not needed. This case suggests that infliximab might offer effective treatment for patients showing superficial thrombophlebitis with RA.